Metropolitan Life Insurance Co. NY Has $1.51 Million Position in FibroGen Inc (NASDAQ:FGEN)

Share on StockTwits

Metropolitan Life Insurance Co. NY boosted its position in shares of FibroGen Inc (NASDAQ:FGEN) by 9.5% during the 2nd quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 24,090 shares of the biopharmaceutical company’s stock after buying an additional 2,091 shares during the quarter. Metropolitan Life Insurance Co. NY’s holdings in FibroGen were worth $1,508,000 as of its most recent SEC filing.

Other large investors have also recently bought and sold shares of the company. Hillhouse Capital Management Ltd. increased its holdings in shares of FibroGen by 3.2% during the second quarter. Hillhouse Capital Management Ltd. now owns 2,686,196 shares of the biopharmaceutical company’s stock worth $168,156,000 after purchasing an additional 83,850 shares during the period. Hilltop Holdings Inc. increased its holdings in shares of FibroGen by 2.9% during the second quarter. Hilltop Holdings Inc. now owns 55,140 shares of the biopharmaceutical company’s stock worth $3,452,000 after purchasing an additional 1,530 shares during the period. Bank of America Corp DE increased its stake in FibroGen by 12.7% in the second quarter. Bank of America Corp DE now owns 109,392 shares of the biopharmaceutical company’s stock valued at $6,849,000 after acquiring an additional 12,288 shares during the last quarter. Voya Investment Management LLC increased its stake in FibroGen by 2.8% in the second quarter. Voya Investment Management LLC now owns 718,643 shares of the biopharmaceutical company’s stock valued at $44,987,000 after acquiring an additional 19,817 shares during the last quarter. Finally, Raymond James & Associates increased its stake in FibroGen by 14.2% in the second quarter. Raymond James & Associates now owns 13,174 shares of the biopharmaceutical company’s stock valued at $825,000 after acquiring an additional 1,640 shares during the last quarter. 76.06% of the stock is currently owned by hedge funds and other institutional investors.

FGEN stock traded up $0.63 during midday trading on Friday, hitting $49.79. The stock had a trading volume of 450,829 shares, compared to its average volume of 505,708. The firm has a market cap of $5.12 billion, a price-to-earnings ratio of -28.78 and a beta of 1.81. The company has a quick ratio of 7.95, a current ratio of 7.95 and a debt-to-equity ratio of 0.19. FibroGen Inc has a 1-year low of $40.74 and a 1-year high of $68.55.

FibroGen (NASDAQ:FGEN) last posted its quarterly earnings results on Tuesday, August 7th. The biopharmaceutical company reported ($0.28) earnings per share for the quarter, beating the consensus estimate of ($0.59) by $0.31. The firm had revenue of $43.95 million during the quarter, compared to the consensus estimate of $28.70 million. FibroGen had a negative net margin of 85.59% and a negative return on equity of 22.60%. Research analysts expect that FibroGen Inc will post -1.32 earnings per share for the current year.

A number of research analysts recently issued reports on the stock. ValuEngine raised shares of FibroGen from a “buy” rating to a “strong-buy” rating in a research note on Thursday, June 21st. BidaskClub lowered shares of FibroGen from a “strong-buy” rating to a “buy” rating in a research report on Tuesday. Mizuho restated a “buy” rating and issued a $74.00 target price on shares of FibroGen in a research report on Tuesday, June 19th. Zacks Investment Research upgraded shares of FibroGen from a “sell” rating to a “hold” rating in a research report on Friday, June 15th. Finally, Leerink Swann set a $82.00 price target on shares of FibroGen and gave the stock a “buy” rating in a report on Tuesday, September 11th. Two research analysts have rated the stock with a hold rating and four have given a buy rating to the company. FibroGen presently has a consensus rating of “Buy” and an average target price of $75.67.

In related news, Director Kalevi Kurkijarvi sold 4,000 shares of the business’s stock in a transaction dated Thursday, July 19th. The shares were sold at an average price of $64.35, for a total transaction of $257,400.00. Following the transaction, the director now directly owns 27,700 shares in the company, valued at $1,782,495. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, CEO Thomas B. Neff sold 39,636 shares of the business’s stock in a transaction dated Wednesday, October 3rd. The shares were sold at an average price of $59.15, for a total transaction of $2,344,469.40. Following the completion of the transaction, the chief executive officer now owns 2,727,574 shares in the company, valued at $161,336,002.10. The disclosure for this sale can be found here. Over the last three months, insiders have sold 257,409 shares of company stock valued at $15,583,967. 8.96% of the stock is currently owned by insiders.

FibroGen Company Profile

FibroGen, Inc, a research-based biopharmaceutical company, discovers, develops, and commercializes therapeutic agents to treat serious unmet medical needs. It is developing Roxadustat, an oral small molecule inhibitor of hypoxia inducible factor prolyl hydroxylases (HIF-PHs) that is in Phase III clinical development for the treatment of anemia in chronic kidney disease; Pamrevlumab, a human-monoclonal antibody that inhibits the activity of connective tissue growth factor, which is in Phase II clinical development for the treatment of idiopathic pulmonary fibrosis, pancreatic cancer, liver fibrosis, and Duchenne muscular dystrophy; and FG-5200, a corneal implant medical device for the treatment of corneal blindness resulting from partial thickness corneal damage.

Recommended Story: Why is the conference call important?

Institutional Ownership by Quarter for FibroGen (NASDAQ:FGEN)

Receive News & Ratings for FibroGen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for FibroGen and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply